Orpathys+Tagrisso improved PFS & OS in EGFRm lung

Summary by AI BETAClose X

HUTCHMED announced positive high-level results from the SAFFRON Phase III trial, demonstrating that ORPATHYS® plus TAGRISSO® significantly improved progression-free and overall survival compared to chemotherapy in patients with MET-driven EGFR-mutated non-small cell lung cancer who had progressed on TAGRISSO®. These results, showing a statistically significant and clinically meaningful benefit, reinforce TAGRISSO® as a backbone therapy and provide clear evidence to support global registrations for the combination, addressing a critical unmet need for patients with poor outcomes and limited treatment options.

Disclaimer*

UK 100

Latest directors dealings